CAD 0.2
(8.11%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - CAD | -100.0% |
2022 | 136.12 Thousand CAD | -50.68% |
2021 | 275.97 Thousand CAD | -60.72% |
2020 | 702.61 Thousand CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
2005 | - CAD | 0.0% |
2004 | - CAD | 0.0% |
2003 | - CAD | 0.0% |
2002 | - CAD | 0.0% |
2001 | - CAD | 0.0% |
2000 | - CAD | 0.0% |
1999 | - CAD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 546.46 Thousand CAD | 0.0% |
2024 Q2 | 521.34 Thousand CAD | 0.0% |
2024 Q3 | 495.35 Thousand CAD | 0.0% |
2023 FY | - CAD | -100.0% |
2023 Q4 | - CAD | -100.0% |
2023 Q1 | 97.04 Thousand CAD | -28.71% |
2023 Q3 | 14.38 Thousand CAD | -74.53% |
2023 Q2 | 56.48 Thousand CAD | -41.8% |
2022 FY | 136.12 Thousand CAD | -50.68% |
2022 Q2 | 208.93 Thousand CAD | -14.05% |
2022 Q3 | 173.48 Thousand CAD | -16.96% |
2022 Q1 | 243.08 Thousand CAD | -11.92% |
2022 Q4 | 136.12 Thousand CAD | -21.54% |
2021 Q1 | - CAD | -100.0% |
2021 Q3 | - CAD | 0.0% |
2021 FY | 275.97 Thousand CAD | -60.72% |
2021 Q4 | 275.97 Thousand CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2020 Q3 | 676.86 Thousand CAD | 0.0% |
2020 Q4 | 702.61 Thousand CAD | 3.8% |
2020 FY | 702.61 Thousand CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q2 | - CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2005 Q2 | - CAD | 0.0% |
2005 Q4 | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
2005 Q3 | - CAD | 0.0% |
2005 Q1 | - CAD | 0.0% |
2004 Q4 | - CAD | 0.0% |
2004 Q1 | - CAD | 0.0% |
2004 FY | - CAD | 0.0% |
2004 Q2 | - CAD | 0.0% |
2004 Q3 | - CAD | 0.0% |
2003 Q3 | - CAD | 0.0% |
2003 Q4 | - CAD | 0.0% |
2003 Q2 | - CAD | 0.0% |
2003 Q1 | - CAD | 0.0% |
2003 FY | - CAD | 0.0% |
2002 Q1 | - CAD | 0.0% |
2002 FY | - CAD | 0.0% |
2002 Q2 | - CAD | 0.0% |
2002 Q3 | - CAD | 0.0% |
2002 Q4 | - CAD | 0.0% |
2001 FY | - CAD | 0.0% |
2000 FY | - CAD | 0.0% |
1999 FY | - CAD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 875.2 Thousand CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | - CAD | NaN% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 6.37 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | - CAD | NaN% |
Oncolytics Biotech Inc. | 290 Thousand CAD | 100.0% |